This site will redirect to thermofisher.com on April 7. Get details >


In Vivo Use of Antibodies


Studies in the mouse model using both in vitro and in vivo assays have resulted in better understanding of immune function and the role of different cell types in the immune response. In vitro functional assays offer the advantage of a minimalist approach, where conditions including type of cell and stimulations can be limited by design. Functions of different cell types such as T cells or B cells, direct interactions between two cell types and intracellular signaling pathways initiated by a specific stimulus can be studied in vitro.

Experiments performed in a living laboratory mouse, however, provide information about the direct biological relevance, collaboration, and interdependence of complex biological processes.

Antibodies are used for in vivo studies where the injected antibody is intended to either deplete a specific cell type, block a receptor or induce activation of cells. eBioscience offers monoclonal antibodies to mouse cell surface antigens and cytokines for in vitro or in vivo functional studies. For functional studies, we recommend using Functional Grade (FG) purified monoclonal antibodies. FG purified antibodies are sterile, contain verified low level of endotoxin (<0.001 ng/µg) and do not have sodium azide (NaN3) or any other preservatives.

The FG purified anti-mouse antibodies are tested by SDS-PAGE and HPLC to ensure purity and integrity of the Ig preparation, by flow cytometry to ensure specificity, by LAL test to determine the level of endotoxin, and by sterility test.

For details about the dosage and the protocol for in vivo injection of mAbs, we have compiled a list of references for each antibody. Users are encouraged to review these papers and other sources in the literature to find the optimal protocol and dosage they need in their experiments.


Anti-Mouse 4-1BBL, mAb: TKS-1 (Cat. No. 16-5901)

  1. J Pathol. 2001 Dec; 195(5): 593-603. Seko Y, Takahashi N, Oshima H, Shimozato O, Akiba H, Takeda K, Kobata T, Yagita H, Okumura K, Azuma M, Nagai R. Expression of tumour necrosis factor (TNF) ligand superfamily co-stimulatory molecules CD30L, CD27L, OX40L, and 4-1BBL in murine hearts with acute myocarditis caused by Coxsackievirus B3.
  2. J Exp Med. 2000 Jan 17; 191(2): 375-80. Akiba H, Miyahira Y, Atsuta M, Takeda K, Nohara C, Futagawa T, Matsuda H, Aoki T, Yagita H, Okumura K. Critical contribution of OX40 ligand to T helper cell type 2 differentiation in experimental leishmaniasis.

Anti-Mouse B7RP-1, mAb: HK5.3 (Cat. No. 16-5985)

  1. J Immunol. 2002 Oct 15; 169(8): 4332-9. Iwai H, Kozono Y, Hirose S, Akiba H, Yagita H, Okumura K, Kohsaka H, Miyasaka N, Azuma M. Amelioration of collagen-induced arthritis by blockade of inducible costimulator-B7 homologous protein costimulation.

Anti-Mouse CD3, mAb: 145-2C11 (Cat. No. 16-0031)

  1. Transpl Immunol. 1999 Dec; 7(4): 207-13. Han WR, Murray-Segal LJ, Gershenzon A, Zhang JG, Hodder AN, Pietersz GA, Mottram PL. Idarubicin-145-2C11-F(ab')2 promotes peripheral tolerance and reduces chronic vascular disease in mouse cardiac allografts.
  2. Clin Exp Immunol. 1996 Feb; 103(2): 233-8. Jacobs F, Dubois C, Carlier Y, Goldman M. Administration of anti-CD3 monoclonal antibody during experimental Chagas' disease induces CD8+ cell-dependent lethal shock.
  3. Transpl Int. 1996; 9(4): 386-91. Kinnaert P, Pradier O, Bournonville B, Habrant C, Goldman M, Van Geertruyden N. Role of CD18-dependent and CD18-independent mechanisms in the increased leukocyte adhesiveness and in the variations of circulating white blood cell populations induced by anti-CD3 monoclonal antibodies.
  4. Transplantation. 1995 Oct 27; 60(8): 828-35. Henrickson M, Reid J, Bellet JS, Sawchuk SS, Hirsch R. Comparison of in vivo efficacy and mechanism of action of antimurine monoclonal antibodies directed against TCR alpha beta (H57-597) and CD3 (145-2C11).

Anti-Mouse CD4, mAb: GK1.5 (Cat. No. 16-0041)

  1. Am J Respir Cell Mol Biol. 1994 Jun; 10(6): 587-93. Gavett SH, Chen X, Finkelman F, Wills-Karp M. Depletion of murine CD4+ T lymphocytes prevents antigen-induced airway hyperreactivity and pulmonary eosinophilia.
  2. Am J Respir Crit Care Med. 1994 May; 149(5): 1286-94. Schuyler M, Gott K, Edwards B, Nikula KJ. Experimental hypersensitivity pneumonitis. Effect of CD4 cell depletion.
  3. Clin Immunol Immunopathol. 1989 Sep; 52(3): 486-506. Ghobrial RR, Boublik M, Winn HJ, Auchincloss H. In vivo use of monoclonal antibodies against murine T cell antigens.
  4. J Immunol. 1989 Feb 1; 142(3): 954-8. Israelski DM, Araujo FG, Conley FK, Suzuki Y, Sharma S, Remington JS. Treatment with anti-L3T4 (CD4) monoclonal antibody reduces the inflammatory response in toxoplasmic encephalitis.
  5. J Immunol. 1988 Jul 15; 141(2): 464-8. Sriram S, Carroll L, Fortin S, Cooper S, Ranges G. In vivo immunomodulation by monoclonal anti-CD4 antibody. II. Effect on T cell response to myelin basic protein and experimental allergic encephalomyelitis.

Anti-Mouse CD8, mAb: 53-6.7 (Cat. No. 16-0081)

  1. J Immunol Methods. 1988 Jul 22; 111(2): 219-26. Goldschmidt TJ, Holmdahl R, Klareskog L. Depletion of murine T cells by in vivo monoclonal antibody treatment is enhanced by adding an autologous anti-rat kappa chain antibody.

Anti-Mouse CD25, mAb: PC61.5 (Cat. No. 16-0251)

  1. Cancer Res. 1999 59: 3128-3133. Onizuka S, Tawara I, Shimizu J, Sakaguchi S, Fujita T, Nakayama E. Tumor Rejection by in Vivo Administration of Anti-CD25 (Interleukin-2 Receptor alpha) Monoclonal Antibody.

Anti-Mouse CD44, mAb: IM7 (Cat. No. 16-0441)

  1. J Autoimmun. 2002 Feb; 18(1): 9-15. Tanaka Y, Makiyama Y, Mitsui Y. Anti-CD44 monoclonal antibody (IM7) induces murine systemic shock mediated by platelet activating factor.
  2. Arthritis Rheum. 1999 Apr; 42(4): 659-68. Mikecz K, Dennis K, Shi M, Kim JH. Modulation of hyaluronan receptor (CD44) function in vivo in a murine model of rheumatoid arthritis.
  3. Jpn J Cancer Res. 1998 Nov; 89(11): 1160-8. Ogoshi T, Ishii S, Mizoi T, Harada N, Sato W, Saito K, Ogawa H, Inabe K, Shiiba K, Matsuno S. CD44H participates in the intrahepatic growth of murine colon 26 adenocarcinoma cells.
  4. Scand J Immunol. 1997 Feb; 45(2): 213-20. Brennan FR, Mikecz K, Glant TT, Jobanputra P, Pinder S, Bavington C, Morrison P, Nuki G. CD44 expression by leucocytes in rheumatoid arthritis and modulation by specific antibody: implications for lymphocyte adhesion to endothelial cells and synoviocytes in vitro.

Anti-Mouse CD45R (B220), mAb: RA3-6B2 (Cat. No. 16-0452)

  1. Clin Exp Immunol. 1990 May; 80(2): 268-73. Asensi V, Himeno K, Kawamura I, Sakumoto M, Nomoto K. In vivo treatment with anti B-220 monoclonal antibody affects T and B cell differentiation.
  2. Immunology. 1989 Oct; 68(2): 204-8. Asensi V, Kimeno K, Kawamura I, Sakumoto M, Nomoto K. Treatment of autoimmune MRL/lpr mice with anti-B220 monoclonal antibody reduces the level of anti-DNA antibodies and lymphadenopathies.

Anti-Mouse CD49d, mAb: R1-2 (Cat. No. 16-0492)

  1. Eur J Immunol. 1993 Mar; 23(3): 682-8. Chisholm PL, Williams CA, Lobb RR. Monoclonal antibodies to the integrin alpha-4 subunit inhibit the murine contact hypersensitivity response.
  2. J Immunol. 1993 Feb 15; 150(4): 1172-82. Ferguson TA, Kupper TS. Antigen-independent processes in antigen-specific immunity. A role for alpha 4 integrin.

Anti-Mouse CD70, mAb: FR70 (Cat. No. 16-0701)

  1. J Pathol. 2001 Dec; 195(5): 593-603. Seko Y, Takahashi N, Oshima H, Shimozato O, Akiba H, Takeda K, Kobata T, Yagita H, Okumura K, Azuma M, Nagai R. Expression of tumour necrosis factor (TNF) ligand superfamily co-stimulatory molecules CD30L, CD27L, OX40L, and 4-1BBL in murine hearts with acute myocarditis caused by Coxsackievirus B3.
  2. J Exp Med. 2000 Jan 17; 191(2): 375-80. Akiba H, Miyahira Y, Atsuta M, Takeda K, Nohara C, Futagawa T, Matsuda H, Aoki T, Yagita H, Okumura K. Critical contribution of OX40 ligand to T helper cell type 2 differentiation in experimental leishmaniasis.

Anti-Mouse CD90 (Thy1), mAb: 30-H12 (Cat. No. 16-0903)

  1. J Immunol. 1983 Apr; 130(4): 1713-8. Seaman WE, Wofsy D, Greenspan JS, Ledbetter JA. Treatment of autoimmune MRL/Ipr mice with monoclonal antibody to Thy-1.2: a single injection has sustained effects on lymphoproliferation and renal disease.

Anti-Mouse CD117 (c-kit), mAb: ACK2 (Cat. No. 16-1172)

  1. J Invest Dermatol. 1999 May; 112(5): 796-801. Ito M, Kawa Y, Ono H, Okura M, Baba T, Kubota Y, Nishikawa SI, Mizoguchi M. Removal of stem cell factor or addition of monoclonal anti-c-KIT antibody induces apoptosis in murine melanocyte precursors.
  2. Development. 1998 Nov; 125(22): 4585-93. Vincent S, Segretain D, Nishikawa S, Nishikawa SI, Sage J, Cuzin F, Rassoulzadegan M. Stage-specific expression of the Kit receptor and its ligand (KL) during male gametogenesis in the mouse: a Kit-KL interaction critical for meiosis.
  3. Am J Physiol. 1996 Nov; 271(5 Pt 1): G762-71. Sato D, Lai ZF, Tokutomi N, Tokutomi Y, Maeda H, Nishikawa S, Nishikawa S, Ogawa M, Nishi K. Impairment of Kit-dependent development of interstitial cells alters contractile responses of murine intestinal tract.
  4. Development. 1996 Apr; 122(4): 1207-14. Yoshida H, Kunisada T, Kusakabe M, Nishikawa S, Nishikawa SI. Distinct stages of melanocyte differentiation revealed by anlaysis of nonuniform pigmentation patterns.

Anti-Mouse CD252 (OX40 Ligand), mAb: RM134L (Cat. No. 16-5905)

  1. J Immunol. 2001 Feb 1; 166(3): 2108-15. Nohara C, Akiba H, Nakajima A, Inoue A, Koh C S, Ohshima H, Yagita H, Mizuno Y, Okumura K. Amelioration of experimental autoimmune encephalomyelitis with anti-OX40 ligand monoclonal antibody: a critical role for OX40 ligand in migration, but not development, of pathogenic T cells.
  2. J Pathol. 2001 Dec; 195(5): 593-603. Seko Y, Takahashi N, Oshima H, Shimozato O, Akiba H, Takeda K, Kobata T, Yagita H, Okumura K, Azuma M, Nagai R. Expression of tumour necrosis factor (TNF) ligand superfamily co-stimulatory molecules CD30L, CD27L, OX40L, and 4-1BBL in murine hearts with acute myocarditis caused by Coxsackievirus B3.
  3. Eur J Immunol. 2000 Oct; 30(10): 2815-23. Yoshioka T, Nakajima A, Akiba H, Ishiwata T, Asano G, Yoshino S, Yagita H, Okumura K. Contribution of OX40/OX40 ligand interaction to the pathogenesis of rheumatoid arthritis.
  4. Blood. 2000 Apr 1; 95(7): 2434-9. Tsukada N, Akiba H, Kobata T, Aizawa Y, Yagita H, Okumura K. Blockade of CD134 (OX40)-CD134L interaction ameliorates lethal acute graft-versus-host disease in a murine model of allogeneic bone marrow transplantation.
  5. J Exp Med. 2000 Jan 17; 191(2): 375-80. Akiba H, Miyahira Y, Atsuta M, Takeda K, Nohara C, Futagawa T, Matsuda H, Aoki T, Yagita H, Okumura K. Critical contribution of OX40 ligand to T helper cell type 2 differentiation in experimental leishmaniasis.

Anti-Mouse CD153/CD30L, mAb: RM153 (Cat. No. 16-1531)

  1. J Pathol. 2001 Dec; 195(5): 593-603. Seko Y, Takahashi N, Oshima H, Shimozato O, Akiba H, Takeda K, Kobata T, Yagita H, Okumura K, Azuma M, Nagai R. Expression of tumour necrosis factor (TNF) ligand superfamily co-stimulatory molecules CD30L, CD27L, OX40L, and 4-1BBL in murine hearts with acute myocarditis caused by Coxsackievirus B3.
  2. J Exp Med. 2000 Jan 17; 191(2): 375-80. Akiba H, Miyahira Y, Atsuta M, Takeda K, Nohara C, Futagawa T, Matsuda H, Aoki T, Yagita H, Okumura K. Critical contribution of OX40 ligand to T helper cell type 2 differentiation in experimental leishmaniasis.

Anti-Mouse CD154/CD40L, mAb: MR1 (Cat. No. 16-1541)

  1. J Clin Invest. 1998 Aug 1; 102(3): 473-82. Blazar BR, Taylor PA, Noelle RJ, Vallera DA. CD4(+) T cells tolerized ex vivo to host alloantigen by anti-CD40 ligand (CD40L:CD154) antibody lose their graft-versus-host disease lethality capacity but retain nominal antigen responses.
  2. Transplantation. 1997 Jul 27; 64(2): 329-35. Markees TG, Phillips NE, Noelle RJ, Shultz LD, Mordes JP, Greiner DL, Rossini AA. Prolonged survival of mouse skin allografts in recipients treated with donor splenocytes and antibody to CD40 ligand.
  3. J Immunol. 1997 Jan 1; 158(1): 29-39. Blazar BR, Taylor PA, Panoskaltsis-Mortari A, Buhlman J, Xu J, Flavell RA, Korngold R, Noelle R, Vallera DA. Blockade of CD40 ligand-CD40 interaction impairs CD4+ T cell-mediated alloreactivity by inhibiting mature donor T cell expansion and function after bone marrow transplantation.
  4. Thyroid. 1996 Aug; 6(4): 267-73. Resetkova E, Kawai K, Enomoto T, Arreaza G, Togun R, Foy TM, Noelle RJ, Volpe R. Antibody to gp39, the ligand for CD40 significantly inhibits the humoral response from Graves' thyroid tissues xenografted into severe combined immunodeficient (SCID) mice.
  5. J Virol. 1996 Apr; 70(4): 2569-75. Green KA, Crassi KM, Laman JD, Schoneveld A, Strawbridge RR, Foy TM, Noelle RJ, Green WR. Antibody to the ligand for CD40 (gp39) inhibits murine AIDS-associated splenomegaly, hypergammaglobulinemia, and immunodeficiency in disease-susceptible C57BL/6 mice.
  6. Eur J Immunol. 1995 Nov; 25(11): 3053-9. Sadlack B, Lohler J, Schorle H, Klebb G, Haber H, Sickel E, Noelle RJ, Horak I. Generalized autoimmune disease in interleukin-2-deficient mice is triggered by an uncontrolled activation and proliferation of CD4+ T cells.
  7. J Exp Med. 1994 Jul 1; 180(1): 157-63. Foy TM, Laman JD, Ledbetter JA, Aruffo A, Claassen E, Noelle RJ. gp39-CD40 interactions are essential for germinal center formation and the development of B cell memory.
  8. Adv Exp Med Biol. 1994; 355: 75-80. van den Eertwegh AJ, Van Meurs M, Foy TM, Noelle RJ, Boersma WJ, Claassen E. In vivo gp39-CD40 interactions occur in the non-follicular compartments of the spleen and are essential for thymus dependent antibody responses and germinal center formation.
  9. J Exp Med. 1993 Nov 1; 178(5): 1567-75. Foy TM, Shepherd DM, Durie FH, Aruffo A, Ledbetter JA, Noelle RJ. In vivo CD40-gp39 interactions are essential for thymus-dependent humoral immunity. II. Prolonged suppression of the humoral immune response by an antibody to the ligand for CD40, gp39.
  10. Science. 1993 Sep 3; 261(5126): 1328-30. Durie FH, Fava RA, Foy TM, Aruffo A, Ledbetter JA, Noelle RJ. Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40.

Anti-Mouse CD178 (FasL), mAb: MFL3 (Cat. No. 16-5911)

  1. J Am Coll Cardiol. 2002 Apr 17; 39(8): 1399-403. Seko Y, Kayagaki N, Seino K, Yagita H, Okumura K, Nagai R. Role of Fas/FasL pathway in the activation of infiltrating cells in murine acute myocarditis caused by Coxsackievirus B3.

Anti-Mouse GR-1, mAb: RB6-8C5 (Cat. No. 16-5931)

  1. BMC Microbiol. 2001; 1(1): 17. Rousseau D, Demartino S, Ferrua B, Francois Michiels J, Anjuere F, Fragaki K, Le Fichoux Y, Kubar J. In vivo involvement of polymorphonuclear neutrophils in Leishmania infantum infection.
  2. Clin Exp Immunol. 2000 Apr; 120(1): 125-33. Chen L, Zhang Z, Sendo F. Neutrophils play a critical role in the pathogenesis of experimental cerebral malaria.
  3. J Immunol. 1997 Feb 1; 158(3): 1383-91. Thomas J, Gangappa S, Kanangat S, Rouse BT. On the essential involvement of neutrophils in the immunopathologic disease: herpetic stromal keratitis.
  4. J Immunol. 1994 Feb 15; 152(4): 1836-46. Czuprynski CJ, Brown JF, Maroushek N, Wagner RD, Steinberg H. Administration of anti-granulocyte mAb RB6-8C5 impairs the resistance of mice to Listeria monocytogenes infection.
  5. J Exp Med. 1994 Jan 1; 179(1): 259-68. Conlan JW, North RJ. Neutrophils are essential for early anti-Listeria defense in the liver, but not in the spleen or peritoneal cavity, as revealed by a granulocyte-depleting monoclonal antibody.

Anti-Mouse IFN gamma, mAb: R4-6A2 (Cat. No. 16-7312)

  1. Infect Immun. 1990 Oct; 58(10): 3225-32. Stevenson MM, Tam MF, Belosevic M, van der Meide PH, Podoba JE. Role of endogenous gamma interferon in host response to infection with blood-stage Plasmodium chabaudi AS.
  2. J Exp Med. 1990 Jan 1; 171(1): 115-27. Sadick MD, Heinzel FP, Holaday BJ, Pu RT, Dawkins RS, Locksley RM. Cure of murine leishmaniasis with anti-interleukin 4 monoclonal antibody. Evidence for a T cell-dependent, interferon gamma-independent mechanism.
  3. J Interferon Res. 1986 Oct; 6(5): 489-97. Havell EA. Purification and further characterization of an anti-murine interferon-gamma monoclonal neutralizing antibody.
  4. Transplantation. 1994 May 15; 57(9): 1367-71. Russell PS, Chase CM, Winn HJ, Colvin RB. Coronary atherosclerosis in transplanted mouse hearts. III. Effects of recipient treatment with a monoclonal antibody to interferon-gamma.

Anti-Mouse IL-4, mAb: 11B11 (Cat. No. 16-7041)

  1. Finkelman FD, Madden KB, Morris SC, Holmes JM, Boiani N, Katona IM, and Maliszewski CR. 1993. Anti-cytokine antibodies as carrier proteins. Prolongation of in vivo effects of exogenous cytokines by injection of cytokine anti-cytokine antibody complexes. J. Immunol. 151: 1235-1244.

Anti-Mouse IL-5, mAb: TRFK5 (Cat. No. 16-7052)

  1. Int Arch Allergy Immunol. 1997 Jan; 112(1): 73-82. Yu CK, Yang BC, Lee SC, Wang JY, Hsiue TR, Lei HY. Dermahagoides-farinae-induced pulmonary eosinophilic inflammation in mice.
  2. J Leukoc Biol. 1997 Dec; 62(6): 778-85. Menezes-de-Lima-Junior O, Werneck-Barroso E, Cordeiro RS, Henriques MG. Effects of inhibitors of inflammatory mediators and cytokines on eosinophil and neutrophil accumulation induced by Mycobacterium bovis bacillus Calmette-Guerin in mouse pleurisy.

Anti-Mouse IL-10, mAb: JES5-2A5 (Cat. No. 16-7102)

  1. Eur J Immunol. 1994 May; 24(5): 1167-71. Marchant A, Bruyns C, Vandenabeele P, Ducarme M, Gerard C, Delvaux A, De Groote D, Abramowicz D, Velu T, Goldman M. Interleukin-10 controls interferon-gamma and tumor necrosis factor production during experimental endotoxemia.
  2. Neuroimmunomodulation. 1995 May-Jun; 2(3): 149-54. Di Santo E, Sironi M, Pozzi P, Gnocchi P, Isetta AM, Delvaux A, Goldman M, Marchant A, Ghezzi P. Interleukin-10 inhibits lipopolysaccharide-induced tumor necrosis factor and interleukin-1 beta production in the brain without affecting the activation of the hypothalamus-pituitary-adrenal axis.
  3. Transplantation. 1999 Mar 27; 67(6): 792-800. Daemen MA, van de Ven MW, Heineman E, Buurman WA. Involvement of endogenous interleukin-10 and tumor necrosis factor-alpha in renal ischemia-reperfusion injury.
  4. J Immunol. 2001 Mar 15; 166(6): 3789-96. Hara M, Kingsley CI, Niimi M, Read S, Turvey SE, Bushell AR, Morris PJ, Powrie F, Wood KJ. IL-10 Is Required for Regulatory T Cells to Mediate Tolerance to Alloantigens In Vivo.

Anti-Mouse MAdCAM-1, mAb: MECA-367 (Cat. No. 16-5997)

  1. Int J Hyperthermia. 2000 Jan-Feb; 16(1): 45-59. Evans SS, Bain MD, Wang WC. Fever-range hyperthermia stimulates alpha4beta7 integrin-dependent lymphocyte-endothelial adhesion.
  2. J Leukoc Biol. 2000 Feb; 67(2): 169-73. Barrett SP, Riordon A, Toh BH, Gleeson PA, van Driel IR. Homing and adhesion molecules in autoimmune gastritis.

Anti-Mouse NK1.1, mAb: PK136 (Cat. No. 16-5941)

  1. J Leukoc Biol. 2002 Dec; 72(6): 1117-21. Kitaichi N, Kotake S, Morohashi T, Onoe K, Ohno S, Taylor AW. Diminution of experimental autoimmune uveoretinitis (EAU) in mice depleted of NK cells.

Anti-Mouse NKG2D (blocking), mAb: CX5 (Cat. No. 16-5882)

  1. J Exp Med. 2003 May 19; 197(10): 1245-53. Lodoen M, Ogasawara K, Hamerman JA, Arase H, Houchins JP, Mocarski ES, Lanier LL. NKG2D-mediated natural killer cell protection against cytomegalovirus is impaired by viral gp40 modulation of retinoic acid early inducible 1 gene molecules.

Anti-Mouse TCR, mAb: H57-597 (Cat. No. 16-5961)

  1. Immunol Lett. 2001 Jan 1; 75(2): 153-8. Kummer U, Zengerle U, Pischel J, Trautmann B, Mailhammer R, Sidell N. Increased in vivo mitogenicity of anti-TCR/CD3 monoclonal antibody through reduced interaction with Fcgamma receptors.
  2. Blood. 1996 Jun 15; 87(12): 5355-69. Drobyski WR, Majewski D. Treatment of donor mice with an alpha beta T-cell receptor monoclonal antibody induces prolonged T-cell nonresponsiveness and effectively prevents lethal graft-versus-host disease in murine recipients of major histocompatibility complex (MHC)-matched and MHC-mismatched donor marrow grafts.

Anti-Mouse gamma delta TCR, mAb: UC7-13D5 (Cat. No. 16-5811)

  1. Microbiol Immunol. 1999; 43(5): 461-9. Ishigami M, Nishimura H, Yoshioka K, Kakumu S, Yoshikai Y. The role of intrahepatic gammadelta-T cells for liver injury induced by Salmonella infection in mouse.
  2. J Neuroimmunol. 1997 Mar; 73(1-2): 169-74. Kobayashi Y, Kawai K, Ito K, Honda H, Sobue G, Yoshikai Y. Aggravation of murine experimental allergic encephalomyelitis by administration of T-cell receptor gammadelta-specific antibody.
  3. Infect Immun. 1993 Aug; 61(8): 3556-8. Williams DM, Grubbs BG, Schachter J, Magee DM. Gamma interferon levels during Chlamydia trachomatis pneumonia in mice.
  4. J Immunol. 1993 Dec 1; 151(11): 6546-58. Peterman GM, Spencer C, Sperling AI, Bluestone JA. Role of gamma delta T cells in murine collagen-induced arthritis.

Anti-Mouse TNF alpha, mAb: MP6-XT3 (Cat. No. 16-7322)

  1. Int Arch Allergy Immunol. 1997 Jan; 112(1): 73-82. Yu CK, Yang BC, Lee SC, Wang JY, Hsiue TR, Lei HY. Dermahagoides-farinae-induced pulmonary eosinophilic inflammation in mice.
  2. J Leukoc Biol. 1997 Dec; 62(6): 778-85. Menezes-de-Lima-Junior O, Werneck-Barroso E, Cordeiro RS, Henriques MG. Effects of inhibitors of inflammatory mediators and cytokines on eosinophil and neutrophil accumulation induced by Mycobacterium bovis bacillus Calmette-Guerin in mouse pleurisy.

Anti-Mouse VEGF Receptor 3, mAb: AFL4 (Cat. No. 16-5988)

  1. Blood. 2000 Jul 15; 96(2): 546-53. Kubo H, Fujiwara T, Jussila L, Hashi H, Ogawa M, Shimizu K, Awane M, Sakai Y, Takabayashi A, Alitalo K, Yamaoka Y, Nishikawa SI. Involvement of vascular endothelial growth factor receptor-3 in maintenance of integrity of endothelial cell lining during tumor angiogenesis.